-
-
-
-
-
-
-
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
-
-
-
-
-
-
-
Bristol Myers Squibb gets EU approval for Sotyktu to treat psoriatic arthritis
-
-
-
-
-
-
-
Raymond James Preview Bristol-Myers Squibb Co. (BMY) Earnings: 'Our updated diluted non-GAAP EPS is $1.49 for 1Q26 '
-
-
-
-
-
-
-
Bristol Myers Squibb wins FDA and EU approvals for Opdivo in Hodgkin lymphoma
-
-
-
-
-
-
-
Iza-bren meets dual endpoints in phase III breast cancer trial
-
-
-
-
-
-
-
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
-
-
-
-
-
-
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $60 at Scotiabank
-
1,200,292 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

